BNP Paribas Financial Markets
TLOG

BNP Paribas Financial Markets’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

BNP Paribas Financial Markets’s Portfolio TLOG Stock Details TLOG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-214
Closed -$890 – 3860
2014
Q3 		$890 Sell
214
-169
-44% -$787 ﹤0.01% 4008
2014
Q2 		$2.26K Buy
+383
New +$2.17K ﹤0.01% 3034

Other funds holding TLOG

CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
FWC
First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BNP Paribas Financial Markets's TLOG Position: Q4 2014 in Review

BNP Paribas Financial Markets sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q4 2014, closing a stake of 214 shares — an estimated $890 sold.

BNP Paribas Financial Markets first reported a position in TLOG in Q2 2014 and held it in 2 quarters. The position peaked at $2.26K in Q2 2014. 31 funds tracked by Wall St. Rank hold TLOG as of Q4 2014.

  • BNP Paribas Financial Markets reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q4 2014 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 214 TetraLogic Pharmaceuticals Corporation shares in Q4 2014, an estimated $890.
  • BNP Paribas Financial Markets first reported a position in TetraLogic Pharmaceuticals Corporation in Q2 2014 and held it in 2 quarters.
  • BNP Paribas Financial Markets's TetraLogic Pharmaceuticals Corporation position peaked at $2.26K in Q2 2014.
  • 31 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q4 2014.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2014, filed 11 Feb 2015.